In recent years, it has been studied how emerging therapies with a high impact on the therapeutic approach to obesity, among which stand out: bariatric surgery (BS) and glucagon-like peptide-1 (GLP-1) analogues, can function in the improvement of the pro-inflammatory state of this disease and its systemic consequences. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.